Fauci expects quick approval of new virus drug

Image
AP Washington
Last Updated : Apr 30 2020 | 8:41 PM IST

The nation's top infectious diseases expert says he expects the U.S. Food and Drug Administration to quickly approve a new experimental drug that showed promising signs in treating patients with COVID-19.

Anthony Fauci tells NBC's Today show Thursday that he anticipates the go-ahead for the emergency use of Remdesivir to happen really quickly. He says he spoke with FDA Commissioner Stephen Hahn on Wednesday, and while Hahn had yet to make a final decision, I would project that we're going to be seeing that reasonably soon.

The drug was shown in a major study to shorten recovery time of hospitalized patients.

Fauci said the drug's manufacturer has committed to scaling production of the drug as quickly as possible as the world hunts for an effective treatment and ultimately a vaccine. Fauci has been working on a project to fast track the development of a vaccine by mass producing formulas that appear safe and effective before they're fully vetted. The goal is to get hundreds of millions of doses to the public by January.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 30 2020 | 8:41 PM IST

Next Story